Simplified quantification and whole-body distribution of [ 18F]FE-PE2I in nonhuman primates: Prediction for human studies

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 295-303

  Varrone, Andrea ^a   Gulyás, Balázs ^a   Takano, Akihiro ^a   Stabin, Michael G ^b   Jonsson, Cathrine ^c   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b VANDERBILT UNIVERSITY   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dopamine transporter; Dosimetry; Noninvasive; Parkinson; PET; Quantification

Indexed keywords

FLUORODEOXYGLUCOSE F 18; N (3 IODO PROP 2 ENYL) 2BETA CARBOFLUOROETHOXY 3BETA (4' METHYLPHENYL)NORTROPANE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACCURACY; ADSORPTION KINETICS; ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; MACACA FASCICULARIS; MACACA MULATTA; MESENCEPHALON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PUTAMEN; RADIOACTIVITY; THALAMUS;

ANIMALS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; MACACA FASCICULARIS; MACACA MULATTA; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84856315375     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.08.004     Document Type: Article

References (42)

1. Varrone A, Halldin C Molecular imaging of the dopamine transporter. J Nucl Med 2010, 51:1331-1334.
2. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
3. Catafau AM, Tolosa E Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004, 19:1175-1182.
4. Mawlawi O, Townsend DW Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009, 36(Suppl 1):S15-S29.
5. Patton JA, Townsend DW, Hutton BF Hybrid imaging technology: from dreams and vision to clinical devices. Semin Nucl Med 2009, 39:247-263.
6. Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med 2008, 49:1000-1008.
7. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009, 36:1639-1650.
8. Goldstein DS, Sewell L. Olfactory dysfunction in pure autonomic failure: implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord 2009, 15:516-520.
9. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990, 47:1290-1298.
10. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996, 37:1760-1765.
11. Tissingh G, Bergmans P, Winogrodzka A, Stoof JC, Wolters EC, Booij J, et al. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1997, 38:1271-1272.
12. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000, 47:493-503.
13. Oaks AW, Sidhu A Synuclein modulation of monoamine transporters. FEBS Lett 2011, 585:1001-1006.
14. Kilbourn MR, Sherman PS, Pisani T Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 1992, 216:109-112.
15. Gordon I, Weizman R, Rehavi M Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996, 298:27-30.
16. Halldin C, Gulyas B, Langer O, Farde L Brain radioligands - state of the art and new trends. Q J Nucl Med 2001, 45:139-152.
17. Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003, 30:1220-1230.
18. Harada N, Ohba H, Fukumoto D, Kakiuchi T, Tsukada H. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: a PET study in the conscious monkey brain. Synapse 2004, 54:37-45.
19. Yaqub M, Boellaard R, van Berckel BN, Ponsen MM, Lubberink M, Windhorst AD, et al. Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. J Cereb Blood Flow Metab 2007, 27:1397-1406.
20. Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett 2009, 19:4843-4845.
21. Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse 2009, 63:871-880.
22. Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging 2007, 34:667-678.
23. Varrone A, Toth M, Steiger C, Takano A, Guilloteau D, Ichise M, et al. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med 2011, 52:132-139.
24. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996, 16:42-52.
25. Lammertsma AA, Hume SP Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
26. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996, 16:834-840.
27. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003, 23:1096-1112.
28. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF Special report: the 1996 guide for the care and use of laboratory animals. Ilar J 1997, 38:41-48.
29. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
30. Farde L, Eriksson L, Blomquist G, Halldin C Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989, 9:696-708.
31. Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, et al. [18F]flumazenil binding to central benzodiazepine receptor studies by PET - quantitative analysis and comparisons with [11C]flumazenil. Neuroimage 2009, 45:891-902.
32. Tsukada H Delivery of radioligands for positron emission tomography (PET) in the central nervous system. Adv Drug Deliv Rev 1999, 37:175-188.
33. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998, 25:565-574.
34. Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med 2003, 44:961-966.
35. Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED Whole-body radiation dosimetry of 2-[18F]fluoro-A-85380 in human PET imaging studies. Nucl Med Biol 2005, 32:869-874.
36. Sprague DR, Chin FT, Liow JS, Fujita M, Burns HD, Hargreaves R, et al. Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med 2007, 48:100-107.
37. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med 1994, 35:764-770.
38. Booij J, Busemann Sokole E, Stabin MG, Janssen AG, de Bruin K, van Royen EA Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998, 25:24-30.
39. ICRP, 1992. Radiological Protection in Biomedical Research. ICRP Publication 62. Ann. ICRP 22 (3).
40. Radiation protection 99: guidance on medical exposure in medical and biomedical research. In: NSaCP Directorate General Environment editor; 1998.
41. Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, et al. Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008, 35:2144-2151.
42. Seneca N, Andree B, Sjoholm N, Schou M, Pauli S, Mozley PD, et al. Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates. Nucl Med Commun 2005, 26:695-700.